VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma's 92% Drug-Failure Problem

Sept. 18, 2026 - Approximately 92% of drugs entering clinical trials fail before receiving regulatory approval, leaving the pharmaceutical industry with a success rate of only about 8%. VivoSim Labs Inc. (NASDAQ: VIVS) is developing human-relevant laboratory models designed to identify potential failures earlier before drug developers commit substantial capital to human trials.

VivoSim's technology uses engineered three-dimensional human tissues, commonly described as 3D biology, to provide a more realistic picture of how experimental medicines may behave inside the human body. Unlike flat cell cultures or animal testing alone, VivoSim's models reproduce important structures and biological functions found in human organs.

The company's NAMkind Trademark platform includes human liver and intestinal tissue models that can help researchers evaluate toxicity and other biological responses during preclinical development. By identifying weak or potentially dangerous compounds earlier, VivoSim could help pharmaceutical companies reduce late-stage failures, control development costs and concentrate resources on candidates with stronger prospects.

Alongside VivoSim Labs Inc. (NASDAQ: VIVS), investors are watching other potential multibagger stocks showing active trading, including Black Titan Corp (NASDAQ: BTTC), LOBO TECHNOLOGIES LTD. (NASDAQ: LOBO), IGC Pharma (NYSE: IGC) and Innventure, Inc. (NASDAQ: INV) as momentum and trading activity put the group in focus.

The commercial potential of the technology is highlighted by its connection to Eli Lilly and Company (NYSE: LLY). Technology associated with VivoSim's intestinal models contributed to identifying a Crohn's disease drug candidate later acquired by Lilly. VivoSim received a $5 million milestone payment related to the divested FXR program and may be eligible for up to $45 million in additional milestone payments.

With the pharmaceutical industry seeking faster, safer and more predictive development methods, VivoSim is targeting one of medicine's largest challenges: improving the odds that promising drug candidates ultimately reach patients.

About the Companies

VivoSim Labs Inc. (NASDAQ: VIVS) develops human-relevant 3D tissue models and predictive technologies for pharmaceutical drug discovery, toxicology testing and preclinical development.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company developing medicines across immunology, diabetes, obesity, neuroscience, oncology and other therapeutic areas.

About The Street Reports

The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=vivosim-labs-inc-nasdaq-vivs-takes-aim-at-pharmas-92-drugfailure-problem]
Country: United States
Website: http://www.thestreetreports.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.